ProCE Banner Activity

Experts Answer HCP Questions on Contemporary HCC Therapy

Clinical Thought
Read this commentary on expert responses to questions asked by healthcare professionals during a webinar series on best practices and emerging strategies in treating patients with hepatocellular carcinoma.

Released: March 21, 2022

Expiration: March 20, 2023

No longer available for credit.

Share

Faculty

Adam Burgoyne

Adam Burgoyne, MD, PhD

Assistant Clinical Professor
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
UC San Diego Moores Cancer Center
La Jolla, California

Lipika Goyal

Lipika Goyal, MD, MPhil

Associate Professor in Medicine
Director of Gastrointestinal Oncology
Stanford School of Medicine
Palo Alto, California

Stacey Stein

Stacey Stein, MD

Assistant Professor of Medicine
Yale University School of Medicine
Section of Medical Oncology
New Haven, Connecticut

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Eisai Inc.

Exelixis

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Adam Burgoyne, MD, PhD

Assistant Clinical Professor
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
UC San Diego Moores Cancer Center
La Jolla, California

Adam M. Burgoyne, MD, PhD, has disclosed that he has received consulting fees from Deciphera, Exelixis, and Genentech.

Lipika Goyal, MD, MPhil

Associate Professor in Medicine
Director of Gastrointestinal Oncology
Stanford School of Medicine
Palo Alto, California

Lipika Goyal, MD, MPhil, has disclosed that she has received consulting fees from Alentis, AstraZeneca, Black Diamond, Exelixis, H3 Biomedicine, Incyte, QED, Servier, Sirtex, and Taiho and research support paid to her institution from Adaptimmune, Bayer, Bristol-Myers Squibb, Eisai, Genentech, Incyte, Leap Therapeutics, Lilly, Loxo Oncology, MacroGenics, Merck, Novartis, NuCana, QED, Relay Therapeutics, Servier, and Taiho.

Stacey Stein, MD

Assistant Professor of Medicine
Yale University School of Medicine
Section of Medical Oncology
New Haven, Connecticut

Stacey M. Stein, MD, has disclosed that she has received consulting fees from AstraZeneca, Eisai, Genentech, Merck, and QED.